Land: Israël
Taal: Engels
Bron: Ministry of Health
ATROPINE SULFATE
TEVA ISRAEL LTD
A03BA01
SOLUTION FOR INJECTION
ATROPINE SULFATE 1 MG/ML
I.M, I.V
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
ATROPINE
ATROPINE
Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus.
2023-01-31
מ"עב תויטבצמרפ תוישעת עבט הנאתה 'חר 1 .ד.ת ן"מח הישעת קראפ , 975 םהוש , 6085001 :לט | 972-3-6864000 | www.tevapharm.com יאמ 2019 ה/דבכ ת/חקור ,ה/אפור , ט תרבח מ עב ןלהל טרופמה עדימ ןוכדע לע עידוהל תשקב : עבט ןיפורטא 1 ל"מ/ג"מ ATROPINE TEVA 1MG/ML דירווה ךותל וא רירשה ךותל הקרזהל הסימת SOLUTION FOR I.M. OR I.V. INJECTION Atropine sulfate 1mg לש הלופמא לכ 1 :הליכמ ל"מ ןולע ןוכדעו םושיר יוכדע תה :םושירה תדועתב הרשואש יפכ היוו Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus. :םיוכדעה רקיע מ רישכתה לש ומשב יויש - Atropine Sulfate ל - Atropine Teva 1mg/ml ליעל טרופמכ היוותהל היוותהה ןוכדע לש תוזירא םוקמב הזיראב תומכב יויש 5 ו - 100 לש תוזיראל ,תולופמא 10 ולופמא ת :בוהצב תומוסמ עדימ תופסות .דבלב םיירקיעה םיוכדעה םילולכ ןלהלש טוריפב .ןכדוע אפורל ןולעה 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. . bradycardia, particularly if complicated by hypotension Treatment of sinus . Antidote in poisoning by organophosphorus 4.2 Posology and method of administration PREANESTHETIC MEDICATION 0.6 mg by intravenous injection immediately before the - The recommended dose is 0.3 _Adults:_ . 60 minutes before the induction - injection 30 by intramuscular anesthesia induction or . The recommended dose is 0.02 mg/kg (maximum dose 0.6 mg) _Children:_ מ"עב תויטבצמרפ תוישעת עבט הנאתה 'חר 1 .ד.ת ן"מח הישעת קראפ Lees het volledige document
Atropine Teva 1mg/ml HS -01/2020 Notification SUMMARY OF PRODUCT CHARACTERISTICS ATROPINE TEVA 1 MG/ML SOLUTION FOR I.V. OR I.M. INJECTION 1. NAME OF THE MEDICINAL PRODUCT Atropine Teva 1 mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains: Active ingredient: Atropine sulfate 1 mg. For the full list of the excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colorless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION PRE-ANESTHETIC MEDICATION _Adults:_ The recommended dose is 0.3-0.6 mg by intravenous injection immediately before the anesthesia induction or by intramuscular injection 30-60 minutes before the induction. _Children:_ The recommended dose is 0.02 mg/kg (maximum dose 0.6 mg). TREATMENT OF SINUS BRADYCARDIA The recommended dose is between 0.3 and 1.0 mg intravenously. ANTIDOTE in poisoning by organophosphorus _Adults_: The recommended dose is 2 mg (intramuscularly or intravenously, taking into account the poisoning severity) every 5-10 minutes, until the skin becomes red and dry, pupils dilate and tachycardia appears. _Children_: The recommended dose is 0.02 mg/kg. 4.3 CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any of the excipients listed in section 6.1. Angle-closure glaucoma, esophageal reflux, pyloric stenosis, gastrointestinal obstruction, ulcerative colitis, prostatic hypertrophy, paralytic ileus, intestinal atony, myasthenia gravis (unless co-administered with anticholinesterase). However, all these contraindications are irrelevant in potentially fatal emergency Atropine Teva 1mg/ml HS -01/2020 Notification situations (such as bradyarrhythmia, poisoning). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR ADMINISTRATION The solution should be clear, colorless and Lees het volledige document